Literature DB >> 17005917

Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport.

Azza A K El-Sheikh1, Jeroen J M W van den Heuvel, Jan B Koenderink, Frans G M Russel.   

Abstract

Methotrexate (MTX) has been used in combination with nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of inflammatory diseases as well as malignancies. Especially at high MTX dosages, severe adverse effects with this combination may occur, usually resulting from an impaired renal elimination. It has been shown that the mechanism of this interaction cannot be fully attributed to inhibition of basolateral MTX uptake in renal proximal tubules. Here, we studied the effect of various NSAIDs on MTX transport in membrane vesicles isolated from cells overexpressing the proximal tubular apical efflux transporters human multidrug resistance protein (MRP) 2/ABCC2 and MRP4/ABCC4. MTX was transported by MRP2 and MRP4 with Km values of 480 +/- 90 and 220 +/- 70 microM, respectively. The inhibitory potency of the NSAIDs was generally higher against MRP4- than MRP2-mediated MTX transport, with therapeutically relevant IC50 values, ranging from approximately 2 microM to 1.8 mM. Salicylate, piroxicam, ibuprofen, naproxen, sulindac, tolmetin, and etodolac inhibited MRP2- and MRP4-mediated MTX transport according to a one-site competition model. In some cases, more complex interaction patterns were observed. Inhibition of MRP4 by diclofenac and MRP2 by indomethacin and ketoprofen followed a two-site competition model. Phenylbutazone stimulated MRP2 and celecoxib MRP4 transport at low concentrations and inhibited both transporters at high concentration. Our data suggest that the inhibition by NSAIDs of renal MTX efflux via MRP2 and MRP4 is a potential new site and mechanism contributing to the overall interaction between these drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005917     DOI: 10.1124/jpet.106.110379

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  66 in total

1.  Isothiocyanate-drug interactions in the human adenocarcinoma cell line Caco-2.

Authors:  Katarzyna Lubelska; Irena Misiewicz-Krzemińska; Małgorzata Milczarek; Jolanta Krzysztoń-Russjan; Elżbieta Anuszewska; Karolina Modzelewska; Katarzyna Wiktorska
Journal:  Mol Cell Biochem       Date:  2012-04-18       Impact factor: 3.396

2.  Ibuprofen is a non-competitive inhibitor of the peptide transporter hPEPT1 (SLC15A1): possible interactions between hPEPT1 substrates and ibuprofen.

Authors:  Diana Højmark Omkvist; Birger Brodin; Carsten Uhd Nielsen
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

Review 3.  Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.

Authors:  Minlu Hu; Sravan Kumar Patel; Tian Zhou; Lisa C Rohan
Journal:  J Control Release       Date:  2015-08-13       Impact factor: 9.776

4.  Role of the efflux transporters BCRP and MRP1 in human placental bio-disposition of pravastatin.

Authors:  Marjan Afrouzian; Rabab Al-Lahham; Svetlana Patrikeeva; Meixiang Xu; Valentina Fokina; Wayne G Fischer; Sherif Z Abdel-Rahman; Maged Costantine; Mahmoud S Ahmed; Tatiana Nanovskaya
Journal:  Biochem Pharmacol       Date:  2018-09-12       Impact factor: 5.858

5.  NDUFA2 complex I mutation leads to Leigh disease.

Authors:  Saskia J G Hoefs; Cindy E J Dieteren; Felix Distelmaier; Rolf J R J Janssen; Andrea Epplen; Herman G P Swarts; Marleen Forkink; Richard J Rodenburg; Leo G Nijtmans; Peter H Willems; Jan A M Smeitink; Lambert P van den Heuvel
Journal:  Am J Hum Genet       Date:  2008-06       Impact factor: 11.025

6.  PharmGKB summary: methotrexate pathway.

Authors:  Torben S Mikkelsen; Caroline F Thorn; Jun J Yang; Cornelia M Ulrich; Deborah French; Gianluigi Zaza; Henry M Dunnenberger; Sharon Marsh; Howard L McLeod; Kathy Giacomini; Mara L Becker; Roger Gaedigk; James Steven Leeder; Leo Kager; Mary V Relling; William Evans; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-10       Impact factor: 2.089

7.  Ibuprofen potentiates the in vivo antifungal activity of fluconazole against Candida albicans murine infection.

Authors:  Sofia Costa-de-Oliveira; Isabel M Miranda; Ana Silva-Dias; Ana P Silva; Acácio G Rodrigues; Cidália Pina-Vaz
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

8.  Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.

Authors:  Isabelle Benz-de Bretagne; Noël Zahr; Amélie Le Gouge; Jean-Sébastien Hulot; Caroline Houillier; Khe Hoang-Xuan; Emmanuel Gyan; Séverine Lissandre; Sylvain Choquet; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

9.  Chalcogenopyrylium dyes as differential modulators of organic anion transport by multidrug resistance protein 1 (MRP1), MRP2, and MRP4.

Authors:  Robert L Myette; Gwenaëlle Conseil; Sean P Ebert; Bryan Wetzel; Michael R Detty; Susan P C Cole
Journal:  Drug Metab Dispos       Date:  2013-03-25       Impact factor: 3.922

10.  Disruption of cAMP and prostaglandin E2 transport by multidrug resistance protein 4 deficiency alters cAMP-mediated signaling and nociceptive response.

Authors:  Z Ping Lin; Yong-Lian Zhu; Dennis R Johnson; Kevin P Rice; Timothy Nottoli; Bryan C Hains; James McGrath; Stephen G Waxman; Alan C Sartorelli
Journal:  Mol Pharmacol       Date:  2007-10-24       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.